Related references
Note: Only part of the references are listed.Zanubrutinib monotherapy for patients with treatment-naive chronic lymphocytic leukemia and 17p deletion
Constantine S. Tam et al.
HAEMATOLOGICA (2021)
Sudden or Cardiac Deaths on IbrutinibBased Therapy Were Associated with a Prior History of Hypertension or Cardiac Disease and the Use of ACE-Inhibitors at Study Entry: Analysis from the Phase III NCRI FLAIR Trial
Talha Munir et al.
BLOOD (2021)
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study
Jan A. Burger et al.
LEUKEMIA (2020)
Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study
John C. Byrd et al.
CLINICAL CANCER RESEARCH (2020)
ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma
Peter Hillmen et al.
FUTURE ONCOLOGY (2020)
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P Sharman et al.
LANCET (2020)
Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenstrom's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATE™ Trial
Judith Trotman et al.
BLOOD (2020)
Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE)
Jan A. Burger et al.
BLOOD (2020)
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia
Thomas J. Kipps et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2019)
Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
T. D. Shanafelt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
UK CLL Forum 5 Year Update on 315 Relapsed Refractory CLL Patients Treated with Ibrutinib in 66 UK and Ireland Centres
George A. Follows
BLOOD (2019)
Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis
Simon Rule et al.
HAEMATOLOGICA (2019)
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
G. Fraser et al.
LEUKEMIA (2019)
Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL)
Othman S. Akhtar et al.
LEUKEMIA & LYMPHOMA (2019)
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
Steven E. Coutre et al.
BLOOD ADVANCES (2019)
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposure
Jan de Jong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
Susan O'Brien et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
J. A. Woyach et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ventricular arrhythmias and sudden death in patients taking ibrutinib
Benjamin L. Lampson et al.
BLOOD (2017)
11q Deletion (del11q) Is Not a Prognostic Factor for Adverse Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Ibrutinib: Pooled Data from 3 Randomized Phase 3 Studies
Thomas J. Kipps et al.
BLOOD (2016)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
